Subscribe to RSS
DOI: 10.1055/s-2002-31521
Decrease of Energy Expenditure Causes Weight Increase in Olanzapine Treatment - A Case Study
Publication History
6. 3. 2001
12. 11. 2001
Publication Date:
23 May 2002 (online)
![](https://www.thieme-connect.de/media/pharmaco/200203/lookinside/thumbnails/10.1055-s-2002-31521-1.jpg)
The aim of this study was to evaluate the mechanisms underlying weight gain induced by the atypical antipsychotic, olanzapine. We performed euglycemic, hyperinsulinemic clamp combined with indirect calorimetry on a 48-year-old male with antisocial personality disorder, alcohol dependence and paranoid ideation before and after one month of olanzapine (10 - 15 mg/day) therapy. The patient gave his informed, written consent for this study. The results were a weight gain of 6 kg and a decrease in both basal (from 1673 to 1613 kcal/24 h) and 3-hour (from 22.8 to 20.2 cal/kg fat free mass/min) energy expenditure. Serum thyroid hormone and high-density lipoprotein cholesterol levels decreased, and the triglyceride and low-density lipoprotein cholesterol levels increased. Insulin sensitivity did not change. We conclude that decreased basal energy expenditure may contribute to weight gain in olanzapine treatment.
References
- 1 Conley R R, Meltzer H Y. Adverse events related to olanzapine. J Clin Psychiatry. 2000; 61 (8) 26-29
- 2 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C, Weiden P J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. l999; 156 1686-1696
- 3 Taylor D M, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand. 2000; 101 416-432
- 4 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998; 44 778-783
- 5 Lindenmayer J P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999; 156 1471
- 6 Devlin M J, Yanovski S Z. Obesity: What mental health professionals need to know. Am J Psychiatry. 2000; 157 854-866
- 7 DeFronzo R A. Glucose intolerance and aging: Evidence for tissue insensitivity to insulin. Diabetes. l979; 28 1091-1111
- 8 Franssila-Kallunki A, Schalin-Jäntti C, Groop L. Effect of gender on insulin resistance associated with aging. Am J Physiol. 1992; 263 (Endocrinol Metab 26) E780-E785
- 9 Ferrannini E. The theoretical basis for indirect calorimetry: a review. Metabolism. 1988; 37 287-301
- 10 Merilainen P T. Metabolic monitor. Inst I Clin Comput. 1987; 4 167-177
- 11 Franssila-Kallunki A. Energy metabolism in insulin resistant states. Academic Dissertation, Helsinki University. Helsinki Yliopistopaino 1994
- 12 Tappy L, Owen O E, Boden G. Effects of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes. 1988; 17 1212-1216
- 13 Franssila-Kallunki A, Groop L. Factors associated with basal metabolic rate in patients with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia. 1992; 35 962-966
- 14 Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand. 1999; 100 3-16
- 15 Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999; 156 312-314
- 16 Herran A, Garcia-Unzueta M T, Amado J A, de la Maza M T, Alvarez C, Vazquez-Barquero J L. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry. 2001; 179 59-62
Matti VirkkunenMD, PhD
Department of Psychiatry, University of Helsinki
Lapinlahti Hospital
PO Box 320
00029 Huch
Finland
Phone: +358 (9) 47 18 12 60
Email: matti.virkkunen@huch.fi